SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48 Combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback